Editorial: microbiome modulation by rifaximin in severe alcoholic hepatitis

Aliment Pharmacol Ther. 2021 Feb;53(4):561-562. doi: 10.1111/apt.16218.

Authors

Gi Soo Youn¹, Ki Tae Suk¹

Affiliation

¹ Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Republic of Korea.

PMID: 33616993
DOI: 10.1111/apt.16218

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Biomarkers
Gastrointestinal Microbiome*
Hepatitis, Alcoholic* / drug therapy
Humans
Rifamycins* / therapeutic use
Rifaximin / therapeutic use

Substances

Biomarkers
Rifamycins
Rifaximin